Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time

Circ J. 2012;76(3):755-7. doi: 10.1253/circj.cj-11-1335. Epub 2012 Jan 31.

Abstract

Background: The distribution of activated partial thromboplastin time (APTT) in nonvalvular atrial fibrillation (NVAF) patients under dabigatran therapy remains to be clarified.

Methods and results: The study population was 196 NVAF patients who were treated with dabigatran in 2011 (126 with 220 mg/day). The APTT values showed a wide distribution among the patients, especially in those with a reduced dose, who seemed to show a high value even in patients without contraindications.

Conclusions: We found a wide distribution of APTT in NVAF patients under dabigatran treatment. High APTT might help screen for bleeding risks among patients under dabigatran, but requires future investigation.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Atrial Fibrillation / drug therapy*
  • Benzimidazoles / administration & dosage*
  • Benzimidazoles / adverse effects
  • Dabigatran
  • Dose-Response Relationship, Drug
  • Female
  • Hemorrhage / chemically induced
  • Humans
  • Male
  • Middle Aged
  • Partial Thromboplastin Time*
  • beta-Alanine / administration & dosage
  • beta-Alanine / adverse effects
  • beta-Alanine / analogs & derivatives*

Substances

  • Benzimidazoles
  • beta-Alanine
  • Dabigatran